Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NCS1 | P62166 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23607121 | 0.85 | ATR (0.51) | ATRLRRK2TOP1HDAC3HDAC1 | |
| SCHEMBL13328295 | 0.78 | LRRK2 (0.78) | NPC1RAB9AMEN1KMT2AATR | |
| SCHEMBL3617783 | 0.77 | DHODH (0.65) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL30961700 | 0.76 | RAB9A (0.54) | NPC1RAB9AMEN1KMT2AATR | |
| SCHEMBL23607124 | 0.76 | CNR1 (0.71) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL23607113 | 0.74 | NPC1 (0.57) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL28900108 | 0.73 | RAB9A (0.62) | NPC1RAB9AMEN1KMT2ARXFP1 | |
| SCHEMBL30961692 | 0.72 | DYRK1A (0.48) | NPC1RAB9AMEN1KMT2AATR | |
| Trifluoroacetic Acid SCHEMBL2302768 | 0.72 | LRRK2 (0.68) | NPC1RAB9AMEN1KMT2AATR | |
| SCHEMBL18553757 | 0.71 | CCNC (0.53) | NPC1RAB9AMEN1KMT2ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | NPC1 2800/4885RAB9A 3171/4885MEN1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.